1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Surrozen, Inc.
  6. News
  7. Summary
    SRZN   US86889P1093

SURROZEN, INC.

(SRZN)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
2.550 USD   -1.54%
05/24Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
AQ
05/24Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week
CI
05/18Surrozen Begins Dosing in Phase 1 Study of Ulcerative Colitis Treatment; Shares Rise Early
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SURROZEN, INC./DE : Other Events (form 8-K)

01/10/2022 | 08:31am EDT

Item 8.01 Other Events.

On January 10, 2022, Surrozen, Inc. issued a press release providing a business update regarding our research pipeline and key developmental goals for 2022 and announced that we now expect to initiate Phase 1 clinical trials of both SZN-1326 and SZN-043 in the third quarter of 2022.

We are also continuing our research efforts within our other preclinical programs, including the nomination of SZN-413, a mono Fzd4 bi-specific antibody, as a candidate for the treatment of retinal vascular associated diseases including wet AMD and diabetic retinopathies.

This Current Report contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "promising," "expect," "continue," "suggest," "target," "potential," "milestone," "opportunities," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our discovery, research and development activities, in particular its development plans and timeline for our product candidates SZN-1326, SZN-043, SZN-413 and potential future candidates, including anticipated clinical development timelines, and the potential for such product candidates to be used to treat human disease. These statements are based on various assumptions, whether or not identified in this Current Report, and on the current expectations of our management. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability.

Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control. Notwithstanding the developments highlighted above, none of these product candidates, or potential product candidates, (i) are on the market, (ii) have gained regulatory approval, (iii) have entered clinical trials or (iv) have ever been tested in humans. Our ability to achieve any financial benefit from these product candidates will depend on obtaining regulatory approvals for and successfully commercializing product candidates. The development of the Company's product candidates and the realization of any potential benefit from the items discussed herein are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to SZN-1326, SZN-043, SZN-413, and potential future drug candidates; our ability to identify, develop and commercialize drug candidates; our ability to advance SZN-1326, SZN-043, SZN-413, or other future product candidates into, and successfully complete, preclinical studies and clinical studies; the effects of the ongoing coronavirus (COVID-19) pandemic or other infectious diseases and natural disasters on our business; our ability to effectively manage growth and expand business operations; and those factors discussed in our Quarterly Report on Form 10-Q under the heading "Risk Factors" and other documents we have filed, or will file, with the U.S. Securities and Exchange Commission. If any of these risks materialize or the underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we presently do not know, or that we currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans, or forecasts of future events and views as of the date of this Current Report. We anticipate that subsequent events and developments will cause our assessments to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing our assessments of any date subsequent to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SURROZEN, INC.
05/24Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
AQ
05/24Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week
CI
05/18Surrozen Begins Dosing in Phase 1 Study of Ulcerative Colitis Treatment; Shares Rise Ea..
MT
05/18Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe ..
AQ
05/18Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to S..
CI
05/18SURROZEN : SZN-043 Induced Quick and Robust Hepatocyte Proliferation in a 14-Day Daily Dos..
PU
05/16Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology De..
AQ
05/11SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu..
AQ
05/11Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11Surrozen Reports First Quarter 2022 Financial Results
AQ
More news
Analyst Recommendations on SURROZEN, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -65,8 M - -
Net cash 2022 45,7 M - -
P/E ratio 2022 -1,47x
Yield 2022 -
Capitalization 89,6 M 89,6 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 83
Free-Float 98,5%
Chart SURROZEN, INC.
Duration : Period :
Surrozen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,55 $
Average target price 16,33 $
Spread / Average Target 541%
EPS Revisions
Managers and Directors
Craig C. Parker President, Chief Executive Officer & Director
Charles Williams Chief Financial Officer
Tim W. Kutzkey Chairman
Trudy Vanhove Chief Medical Officer
Wen-Chen Yeh Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
SURROZEN, INC.-60.40%90
MODERNA, INC.-46.53%54 016
LONZA GROUP AG-28.07%42 292
IQVIA HOLDINGS INC.-26.37%39 319
SEAGEN INC.-10.44%25 487
ICON PUBLIC LIMITED COMPANY-29.73%17 693